Consensus Meeting for Asian-Pacific BPH Guideline

Similar documents
Overview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014

EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION

GUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (BPO)

EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION

GUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey

Treating BPH: Comparing Rezum UroLift and HoLEP

EAU GUIDELINES POCKET EDITION 3

Surgical procedures for benign prostatic hyperplasia: A nationwide survey in Japan

Management of LUTS. Simon Woodhams February 2012

Benign Prostatic Hyperplasia (BPH)

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Chapter 2: Methodology

50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?

Benign Prostatic Hyperplasia (BPH):

Chapter 3: Results of the Treatment Outcomes Analyses

What is Benign Prostatic Hyperplasia (BPH)?

Management of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005

NOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano

Management of LUTS after TURP and MIT

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center

Benign Prostatic Hyperplasia: Update on Innovative Current Treatments

EFFICACY OF LASER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA TREATMENT

PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA

Executive Summary. Non-drug local procedures for treatment of benign prostatic hyperplasia 1. IQWiG Reports - Commission No.

Clinical guideline Published: 23 May 2010 nice.org.uk/guidance/cg97

Benign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

LUTS after TURP: How come and how to manage? Matthias Oelke

The Enlarged Prostate Symptoms, Diagnosis and Treatment

POLICIES AND PROCEDURE MANUAL

BPH OVERVIEW / MANAGEMENT. Richard L Haddad Norwest Private Hospital 17 Oct 2018

Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต

All about the Prostate

What can the primary care physician do? Brian W. Ellis

Rezūm procedure for the Prostate

Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran

MODULE 3: BENIGN PROSTATIC HYPERTROPHY

As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5

BPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.

BPH with persistently elevated PSA 아주대학교김선일

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Policy for Prostatism/Lower Urinary Tract Symptoms in men

Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine

Can men with prostates sized 80 ml or larger be managed conservatively?

Clinical Policy Title: Management of benign prostatic hyperplasia (BPH)

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH

AMERIHEALTH / INDEPENDENCE BLUE CROSS

Benign prostatic hyperplasia (BPH)

The Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes

Original Policy Date

Diagnosis and Mangement of Nocturia in Adults

Prostate Artery Embolization

Male Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon

Early-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP)

The management of lower urinary tract symptoms in men

GENDER HEALTH. Benign Prostatic Hyperplasia. Medical and Surgical Treatment Options

BPH: a present and future perspective on health impact

Initial Experience of High Power Diode Laser for Vaporization of Prostate Muhammad Rafiq Zaki, Mujahid Hussain, Tahir Mehmood, Murtaza Hiraj

Transurethral Laser Technology: Treatments for BPH

Association of BPH with OAB: The Plumbing or the Pump?

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?

Original Article - Lasers in Urology. Min Ho Lee, Hee Jo Yang, Doo Sang Kim, Chang Ho Lee, Youn Soo Jeon

ISSN: (Print) (Online) Journal homepage:

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE

Submitted: August 15, Accepted: September 10, Published: October 15, 2018.

VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

LUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group

Lower Urinary Tract Symptoms

Comparison of outpatient versus inpatient transurethral prostate resection for benign prostatic hyperplasia: Comparative, prospective bi-centre study

Chapter 3: Results of the Treatment Outcomes Analyses

Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care

Wednesday 25 June Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario

Long-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia

Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study

AN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION

Case studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES

Name of Policy: Transurethral Microwave Thermotherapy

New Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital

Holmium Laser Enucleation of the Prostate: Modified Morcellation Technique and Results

Prostate Gland Volume and Its Relationship to Complications of Benign Prostatic Enlargement

A Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia

Managing urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester

Frank P. Begun, M.D. Associate Professor, Urology

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results

Dichotomous Estimation of Prostate Volume: A Diagnostic Study of the Accuracy of the Digital Rectal Examination

Energy Delivery Systems for Treatment of Benign Prostatic Hyperplasia

LUTforum Highlights Christian Gratzke LMU Munich

PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment

Benign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy

Prostate Disease. Chad Baxter, MD

Can 80 W KTP Laser Vaporization Effectively Relieve the Obstruction in Benign Prostatic Hyperplasia?: A Nonrandomized Trial

Prostate Overview Quiz

Transcription:

Consensus Meeting for Asian-Pacific BPH Guideline Byung Ha Chung Yonsei University Health System

S a t e l l i t e S y m p o s i u m I Contents Diagnosis and Treatment Guidelines for BPH Prostate Volume PSA value Symptom Assessment Questionaires Treatment Patterns

Diagnosis and Treatment Guidelines for BPH (1) AUA 2010, EAU 2010 Guidelines (2) Survey - Australia, China, Chinese Taipei, Hong Kong, Indonesia, Japan, Korea, Malaysia, Philippines

AUA (2003, 2010) EAU (2004, 2010) TRUS Optional Optional UFM / PVR Optional Recommended

2010 AUA Guidelines Basic Management Detailed Management

Creatinine: Not routinely recommended No or Little Bother Reassurance & F/U Predominant Significant Nocturia Freq/Vol Chart Initial Diagnosis Hx & P/Ex (DRE) Severity & Bother (AUA-SI) Urinalysis Serum PSA Freq/Vol Chart AUA-SI Score Bother Score Bothersome LUTS If life expectancy >10 yrs and/or if When the Dx significant of Pca can nocturia modify is the a predominant management Sx No Polyuria Success Continue Tx FAIL

PSA <1.5 ng/ml PSA >1.5 ng/ml

Several Commments 5ARI - prevent progression of LUTS secondary to BPH - reduce the risk of urinary retention and future prostate-related surgey - Should NOT be used, if without prostate enlargement Other indication of 5ARI : Refractory hematuria preumably due to prostate bleeding (after exclusion of any other causes of hematuria)

Several Commments Antimuscarinics - effective treatment alternatives when LUTS are predominantly irritative (without an elevated PVR) Complementary and Alternative Medicines (CAM) - No dietary supplement, combination phytotherapeutic agent or other nonconventional therapy is recommended - Available data : Saw palmetto DOES NOT have meaningful effect - Urticadioica : don t provide a sufficient evidence base

Several Commments Minimally Invasive Therapy Safety recommendations for : - Transurethral needle ablation of the prostate (TUNA) - Transurethral microwave thermotherapy (TUMT)

Several Commments Surgical Procedures Indication of Surgery : - renal insufficiency secondary to BPH - recurrent UTIs, bladder stones or gross hematuria due to BPH - LUTS refractory to other therapies - The presence of a bladder diverticulum is not an absolute indication ( unless associated with recurrent UTI or progressive bladder dysfunction )

Several Commments TURP Appropriate and effective primary alternative for surgical therapy Open Prostatectomy Appropriate and effective treatment alternative for men with : - moderate to severe LUTS and/or who are significantly bothered by these symptoms. The choice of approach should be based on : - the patient s presentation, anatomy, the surgeon s level of training & experience, and a discussion of the potential benefit and risks for complications.

Several Commments Effective alternatives to TURP & Open prostatectomy - Laser Therapies Transurethral holmium laser ablation of the prostate (HoLAP) Transurethral holmium laser enucleation of the prostate (HoLEP) Holmium laser resection of the prostate (HoLRP) Photoselective vaporization of the prostate (PVP) The choice of approach should be based on : the patient s presentation, anatomy, the surgeon s level of training and experience, and a discussion of the potential benefit and risks for complications.

Several Commments Laser Therapies - Emerging evidence suggests a possible role of transurethral enucleation and laser vaporization as options for men with very large prostates ( > 100 g). - There are insufficient data on which to base comments on bleeding. Other Surgical Options Transurethral incision of the prostate (TUIP) Transurethral vaporization of the prostate (TUVP) Laparoscopic and robotic prostatectomy (considered investigational)

EAU Guidelines

2004 EAU Guidelines

Watchful Wainting Alpha Blockers 5ARIs Several Commments Men with mild symptoms are suitable for watchful waiting Men with LUTS should be offered lifestyle advice prior to or concurrent with treatment α-blockers should be offered to men with moderate to severe LUTS Prevent disease progression with regard to AUR and need for surgery

Several Commments Antimuscarinics - moderate to severe LUTS, predominantly bladder storage symptoms - caution is advised in men with bladder outlet obstruction Phytotherapy The Guidelines committee is unable to make specific recommendations about phytotherapy of male LUTS Desmopressin for the treatment of nocturia based on a polyuric background

Several Commments Alpha Blocker + 5ARI - Moderate to severe LUTS, enlarged prostates, and reduced Qmax (men likely to develop disease progression) - Combination treatment is NOT recommended for short-term therapy ( < 1 yr) Alpha Blocker + Antimuscarinics if symptom relief has been insufficient with the monotherapy of either drug PDE5Is inhibitors reduce moderate to severe male LUTS

Prostate Volume (1) Large volume : Cut-off points? (2) Volume Measurement : DRE / TRUS / Abdominal SONO / MRI

(1) Large volume : Cut-off points?

The prostate volumes of Korean men are smaller than those of the westerner! Racial difference Korean Westerner Age group Chung, et al. Roehrborn, et al. Mochtar, et al. 50-59 60-69 70-79 All Baseline PSA (ng/ml) 1.6 2.1 2.6 Baseline PV (ml) 31.5 39.3 37.7 Baseline PSA (ng/ml) 2.4 2.7 3.2 Baseline PV (ml) 37.4 44.8 44.5 Baseline PSA (ng/ml) 2.9 2.9 3.8 Baseline PV (ml) 36.9 43.7 43.9 Baseline PSA (ng/ml) 2.2 2.6 3.1 Baseline PV (ml) 36.9 43.7 43.9 Chung et al, BJU int 2006, Roehrborn et al, Urology 1999, Mochtar et al, Eur Urol 2003

Large volume : Cut-off points? Chung et al, Korean J Urol 2006-5716 Korean men - PVs were obtained from Roehrborn s equations - ROC curves - to evaluate the ability of PSA to predict threshold PV - Average cut-off for Korean men 35cc - Age Related PSA for PV >35 cc 50 s 1.2 ng/ml 60 s 1.6 ng/ml 70 s 2.0 ng/ml - Caucasian 40 cc PV = Korean PV of 35 cc s

(2) Volume Measurement : DRE / TRUS / Transabdominal US / MRI

TRUS vs MRI vs RP specimen Chung et al, Urol int 2006 Accuracy : MRI > TRUS However, TRUS is inexpensive & almost as accurate as MRI.

TRUS vs Transabdominal US Stravodimos KG et al, Int Urol Nephrol 2009 * TRUS is more accurate than transabdominal ultrasound in predicting adenoma volume - its standard use might lead to fewer open approaches, with consequent less morbidity and hospitalization.

Survey Results Volume Measurement : TRUS vs. Abdominal SONO

Survey Initial evaluation TRUS vs. Abdo SONO DRE TRUS (Routine) Abdominal SONO KOREA Yes Yes No JAPAN (Hideyuki Akaza) Yes Yes JAPAN (Tetsuro Matsumoto) Yes Yes JAPAN (Tomonori Habuchi) Yes Yes Yes (optional) JAPAN (Yasutomo Nasu) Yes No Yes CHINA (Ming Li) HONG KONG (Anthony Ng ) Yes No No CHINESE TAIPEI (Hong-Jen Yu ) Yes No CHINESE TAIPEI (Yao-chi Chuang) Yes Yes (for fresh pt) AUSTRALIA (David Malouf) Yes Yes (optional) PHILIPINES (Dennis Serrano) Yes No Yes INDONESIA (Doody Soebadi) Yes No Yes MALAYSIA (Zulkifli Zainuddin)

PSA value - PSA reference according to prostate volume - PSA reference in Korean men

Relationship between serum PSA and prostate volume in Korean men Chung et al, BJU 2006

- Log serum PSA level & log PV were linearly related to age - 35.9% increase in serum PSA level with each decade of life - 12.4% increase in PV with each decade of life. Predictive PV vs. serum PSA level at various ages Conclusions - PSA-PV relationship in Korean men is similar to that in Caucasians - But, Korean men have a slightly lower PSA level and a smaller PV than Caucasians.

Koreans have different reference for PSA!! Comparison of serum PSA levels among white, Japanese, and Korean men Age Range ( yr ) Reference range (95 th percentile level, ng/ml) White Japanese Korean 1) Korean 2) Korean 3) 30-39 - - 1.8 2.35 1.88 40-49 2.5 2.0 2.0 2.36 1.92 50-59 3.5 3.0 2.5 2.96 2.37 60-69 4.5 4.0 3.9 3.78 3.56 70-79 6.5 5.0 5.8 7.49 5.19 A given serum PSA value for a Korean man has a different clinical meaning for a white man of the same age!! 1) Lee, et al. Urology, 2000 2) Ku, et al. Urology, 2002 3) Jeon, et al. Korean J Urology, 2006

PSA and Prostate Volume ; Chinese Taipei Chang et al, J Urol 2006 Caucasian Taiwanese Caucasian Prostate Volume PSA Prostate Volume Japanese Taiwanese PSA ** PSA per unit prostate volume Taiwanese > Caucasian Taiwanese = Japanese

Other Asian countries are also trying to establish their own PSA reference range! (1) Kumamoto et al, BJU 1995 (2) Dalin He et al Urology 2004 (3) Kehinde et al BJU 2005

Survey PSA vs. Prostate Volume PSA vs. Prostate Volume KOREA JAPAN (Tetsuro Matsumoto) JAPAN (Hideyuki Akaza) Yes PSAD>0.15 : PBx Yes, but not official CHINA/ HONG KONG CHINESE TAIPEI ( Hong-Jen Yu ) AUSTRALIA PHILIPINES INDONESIA PSAD to decide PBx No No No MALAYSIA

Symptom Assessment Questionaires (1) Valiadation of IPSS - in each country s own language (2) Other paticular questionaires of own country?

Survey Linguistic validation of IPSS IPSS linguistic validation (Own language) Other Questionaire KOREA Yes. JAPAN Yes. CHINA/ HONG KONG Yes. CHINESE TAIPEI Yes. AUSTRALIA Yes. PHILIPINES Yes. INDONESIA Yes. MALAYSIA.

Treatment Patterns (1) Results of Korean Survey (2) Medical Treatment - Alpha blocker, Vasopressin - 5ARI - Antimuscarinics (3) Indication of Surgery and Preferred Choice of Surgery

(1) Results of Korean Survey

Practice Patterns in The Medical Treatment of Benign Prostatic Hyperplasia in Korea ; A Nationwide Survey on 2007 BH Chung et al. YMJ 2008

Drug of choice for initial treatment option for BPH patients Alpha-blocker mono therapy was most common The proportion of the combination therapy was somewhat high in general hospital Drug of choice a-blocker monotherapy Combination therapy (a-blocker + 5ARIs) a-blocker + crude drug (CAM) 5ARIs monotherapy [Base: N = 250] Chung et al, YMJ 2008

[P < 0.05 : *, P < 0.01 : **] Drug of choice by the severity grade of BPH The role of the combination therapy was increased by the severity

(2) Medical Treatment - Alpha blocker, Vasopressin - 5ARI - Antimuscarinics (3) Indication of Surgery & Preferred Choice of Surgery

Survey Results - Medical Treatment - Surgical Treatment

Survey Alpha-blocker, Vasopressin KOREA JAPAN (Hideyuki Akaza) JAPAN (Tetsuro Matsumoto) CHINA / HONG KONG CHINESE TAIPEI ( Hong-Jen Yu ) CHINESE TAIPEI (Yao-chi Chuang) AUSTRALIA (David Malouf) PHILIPINES (Dennis Serrano) INDONESIA (Doody Soebadi) MALAYSIA (Zulkifli Zainuddin)

Survey 5ARI Ix of 5ARI KOREA Vol > 30 gm JAPAN (Hideyuki Akaza). JAPAN (Tetsuro Matsumoto) Vol > 30 gm CHINA / HONG KONG. /. CHINESE TAIPEI ( Hong-Jen Yu ) CHINESE TAIPEI (Yao-chi Chuang) Vol > 40 gm Vol > 40gm & unsatifactory to AB AUSTRALIA (David Malouf). PHILIPINES (Dennis Serrano) Vol > 30 gm & siginificant LUTS INDONESIA (Doody Soebadi). MALAYSIA (Zulkifli Zainuddin).

Survey BPH-related Surgery Surgery Option Open Prostatectomy KOREA JAPAN (Hideyuki Akaza) JAPAN (Tetsuro Matsumoto) TURP, PVP, KTP, HoLEP, TUNA,TUMT Patient s preference TURP (+) HOLEP (-) PVP(-) >50-75 & TURP is risky Large, hard bladder stone Large Sx diverticulum >80-100 gm CHINA / HONG KONG CHINESE TAIPEI ( Hong-Jen Yu ) CHINESE TAIPEI (Yao-chi Chuang) AUSTRALIA (David Malouf) PHILIPINES (Dennis Serrano) INDONESIA (Doody Soebadi) MALAYSIA (Zulkifli Zainuddin) PVP(-), TUMT(+) Laser (Holmium or Thulium) TURP,HOLEP,PVP depends on operators 80-100 gm + bladder stone > 100 gm Large bladder stone

S a t e l l i t e S y m p o s i u m I Conclusions (1) Diagnosis and Treatment Guidelines for BPH The guidelines of Asian-Pacific countries seem to be consistent with EAU / AUA guidelines. Except - TRUS : mandatory? - TRUS or Transabdominal US? PSA / Vol or PSA reference Needs to have an Asian-Pacific-Specific reference!

S a t e l l i t e S y m p o s i u m I Conclusions (2) Symptom Assessment Questionaires Satisfactory in Asian-Pacific countries Treatment Patterns for BPH Medical Treatment Surgical Treatment The practice patterns of Asian-Pacific countries seem to be consistent with EAU / AUA guidelines. Surgical Options Somewhat Different Cost, Surgeon s Experience / Preference

S a t e l l i t e S y m p o s i u m I Thank You for Your Attentions!!